Fibrocell Science (FCSC), an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints.
FCSC’s gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
FCSC has a collaboration agreement with Intrexon Corporation (XON)for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints.
The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009; was incorporated in 1992 and is based in Exton, Pennsylvania.
March 7, 2017
RegMed Investors’ (RMi) closing bell analysis: where is the bong - no one is feelin’ the high
March 6, 2017
RegMed Investors’ (RMi) closing bell analyses, sector challenge - fear of failure as they …
March 3, 2017
RegMed Investors’ (RMi) closing bell analysis, following the sector day by day
March 2, 2017
RegMed Investors’ (RMi) closing bell analysis, biotech is breaking out and cell therapy is breaking down
March 1, 2017
RegMed Investors’ (RMi) closing bell analysis, the sector that wished it could
February 28, 2017
RegMed Investors’ (RMi) closing bell analysis, CEO compensation remains strong
February 27, 2017
RegMed Investors’ (RMi) closing bell analysis, finally an up day
February 25, 2017
RegMed Investors’ (RMi) closing bell analysis, the sector exposes its downside again
February 22, 2017
RegMed Investors’ (RMi) closing bell analysis, the sector falls on the sidewalk again
February 21, 2017
RegMed Investors’ (RMi) closing bell analysis, what are investors feeling?
35 companies, 1 interpreter!
Insight, foresight and recommendation
Fibrocell Science (FCSC) has always been (to me) a disappointment. January '18 opened at $0.69, rolled barely up and slightly down to open 2/1 at $0.66 and sliding into second base at $0.67 on 2/16 ...Still early with a submission of an IND Application with the U.S. FDA for FCX-013, the Company’s gene therapy candidate for the treatment of moderate to severe localized scleroderma.
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.